Ambria Capital is on a mission to empower early-stage companies, in the mental health and technology spaces, that have the ambition and ability to transform markets and make a difference in millions of lives. The overwhelming success of psychedelics in clinical trials offers people real hope. The scientific evidence is clear that psychedelics far outperform traditional antidepressants and some of these compounds are rapidly approaching regulatory approval. With momentum building and more amazing entrepreneurs emerging across the clinical, manufacturing, and commercial spaces, there is little doubt we are witnessing an awesome mental health revolution and a massive market opportunity.
People
You last contacted this investor on .